Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing covers the month of April 2025, specifically detailing share repurchases executed on April 14, 2025. The company is a Foreign Private Issuer filing under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics and Transaction Details
The filing details a specific block of share buybacks executed as part of an existing program. No revenue, profit, or cash flow data is provided in this document.
- Shares Purchased (April 14, 2025): 918,500 ordinary shares.
- Price Range: Lowest price paid was 1,305.00 GBp; highest price paid was 1,328.00 GBp.
- Volume-Weighted Average Price (VWAP): 1,315.40 GBp.
- Trading Venue: London Stock Exchange (XLON).
- Broker: Citigroup Global Markets Limited.
- Treasury Shares Held: 197,381,404 ordinary shares (post-transaction).
- Shares in Issue (excluding Treasury): 4,117,853,751.
- Total Voting Rights: 4,117,853,751.
Material Changes and Program Progress
The purchase on April 14, 2025, was effected pursuant to a non-discretionary agreement entered into with the broker on February 24, 2025. Since the inception of this specific agreement on February 24, 2025, the Company has purchased a total of 28,311,101 ordinary shares. The purchased shares are held as Treasury shares and do not carry voting rights.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in the GSK 2024 Annual Report on Form 20-F (pages 277 to 285). No unusual items or contingencies are disclosed in this specific filing.
Investor Verification Checklist
- Verify the total remaining authorization under the buyback program initiated on February 24, 2025, to assess future capital return capacity.
- Confirm the impact of the 197,381,404 treasury shares on earnings per share (EPS) calculations, as these shares are excluded from the denominator.
- Review the GSK 2024 Annual Report on Form 20-F (pages 277-285) for the specific risk factors referenced in the cautionary statement.
- Monitor subsequent Form 6-K filings to track the pace of the remaining buyback program execution.